Abbott CEO granted options and stock awards

Abbott Laboratories Chairman and CEO Robert B. Ford reported equity awards rather than open-market trades.

Rhea-AI Filing Summary

Abbott Laboratories Chairman and CEO Robert B. Ford reported equity awards rather than open-market trades. He acquired 344,066 options with a zero-dollar grant price under the Abbott Laboratories 2017 Incentive Stock Program, scheduled to become exercisable in three equal annual installments starting on February 24, 2027.

Ford also received a performance-based restricted stock award of 83,464 common shares with a three-year term, with no more than one-third vesting in any year, contingent on Abbott reaching a minimum return-on-equity target. An additional 216,203 common shares are reported as held indirectly through the Ford Family Trust, where he serves as co-trustee.

Insider Trade Summary

Grant/Award: 427,530 shares

Grant/Award 3 txns

Insider Ford Robert B

Role CHAIRMAN AND CEO

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	344,066	$0.00	$0.00
Grant/Award	Common shares without par value	83,464	$0.00	$0.00
holding	Common shares without par value	--	--	--

Holdings After Transaction: Option (right to buy) — 344,066 contracts (Direct); Common shares without par value — 336,769 shares (Direct); Common shares without par value — 216,203 shares (Indirect, Ford Family Trust)

Footnotes (3)

1. F1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
2. F2. Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust.
3. F3. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 114,688 on February 24, 2027, 114,689 on February 24, 2028, and 114,689 on February 24, 2029.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Abbott (ABT) CEO Robert B. Ford receive?

Robert B. Ford received a grant of 344,066 stock options and a performance-based restricted stock award of 83,464 common shares under Abbott’s 2017 Incentive Stock Program, both reported as acquisitions rather than open-market purchases or sales.

How do Robert B. Ford’s new Abbott (ABT) stock options vest?

Ford’s 344,066 employee stock options vest in three annual increments: 114,688 options on February 24, 2027, 114,689 on February 24, 2028, and 114,689 on February 24, 2029, providing a staggered long-term incentive structure tied to continued service.

What are the conditions on Robert B. Ford’s performance-based Abbott (ABT) shares?

The 83,464 performance-based restricted shares have a three-year term. No more than one-third may vest in any year, and vesting depends on Abbott reaching a minimum return-on-equity target, aligning Ford’s compensation with the company’s profitability performance over time.

Are any of Robert B. Ford’s Abbott (ABT) shares held indirectly?

Yes. The filing reports 216,203 Abbott common shares held indirectly in the Ford Family Trust dated June 2, 2014. Ford is a co-trustee of this trust, which means these holdings are attributed to him as indirect beneficial ownership in the disclosure.

Did Robert B. Ford buy or sell Abbott (ABT) shares on the market?

The filing shows no open-market purchases or sales. Instead, it reports equity compensation: a large stock option grant and a performance-based restricted stock award, both with a grant price of zero, reflecting compensation rather than regular trading activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 06:21 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ford Robert B

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHAIRMAN AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	02/24/2026		A		83,464(1)	A	$0	336,769	D
Common shares without par value								216,203(2)	I	Ford Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)(3)	$114.6	02/24/2026		A		344,066		02/24/2027	02/23/2036	Common Shares	344,066	$0	344,066	D

Explanation of Responses:

1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

2. Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust.

3. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 114,688 on February 24, 2027, 114,689 on February 24, 2028, and 114,689 on February 24, 2029.

	/s/ Robert B. Ford by Jessica H. Paik, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.